Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus

Item

http://www.wikidata.org/entity/Q38106983

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus

@en

type

Item

label

Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus

@en

prefLabel

Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus

@en

P1476

Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus

@en

P2093

Andre C Schuh

http://www.w3.org/2001/XMLSchema#string

Andrea K Kew

http://www.w3.org/2001/XMLSchema#string

Brian Leber

http://www.w3.org/2001/XMLSchema#string

Irwindeep Sandhu

http://www.w3.org/2001/XMLSchema#string

Jeannine Kassis

http://www.w3.org/2001/XMLSchema#string

John Ashkenas

http://www.w3.org/2001/XMLSchema#string

John M Storring

http://www.w3.org/2001/XMLSchema#string

Joseph M Brandwein

http://www.w3.org/2001/XMLSchema#string

Michelle Geddes

http://www.w3.org/2001/XMLSchema#string

Mitchell Sabloff

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Part

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

P304

141-164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23675565

http://www.w3.org/2001/XMLSchema#string

P932

3649813

http://www.w3.org/2001/XMLSchema#string